Reyvow Side Effects

Generic name: lasmiditan

Medically reviewed by Philip Thornton, DipPharm. Last updated on Nov 18, 2024.

Note: This document provides detailed information about Reyvow Side Effects associated with lasmiditan. Some dosage forms listed on this page may not apply specifically to the brand name Reyvow.

Applies to lasmiditan: oral tablet.

Serious side effects of Reyvow

Along with its needed effects, lasmiditan (the active ingredient contained in Reyvow) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking lasmiditan:

Other side effects of Reyvow

Some side effects of lasmiditan may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

For healthcare professionals

Applies to lasmiditan: oral tablet.

General adverse events

The most commonly reported adverse reactions have included dizziness, fatigue, paresthesia, and sedation.^[Ref]

Nervous system

• Very common (10% or more): Dizziness (up to 17%)
• Common (1% to 10%): Sedation (includes somnolence), paresthesia (includes oral paresthesia, oral hypoesthesia, and hypoesthesia)
• Frequency not reported: Vertigo, incoordination, lethargy, tremor, cognitive changes, speech abnormalities, impaired driving performance, serotonin syndrome

Vertigo, incoordination, lethargy, tremor, cognitive changes, and speech abnormalities were reported in less than 2% of patients receiving this drug, but more frequently than those receiving placebo.

In a clinical study evaluating driving performance 90 minutes after administration of this drug, a dose-dependent impairment of computer-based simulated driving performance was observed.

Hypersensitivity

• Uncommon (0.1% to 1%): Hypersensitivity including angioedema, rash and photosensitivity

Cardiovascular

• Frequency not reported: Chest discomfort, palpitations, heart rate decreases, increased blood pressure

Chest discomfort and palpitations were reported in less than 2% of patients receiving this drug, but more frequently than those receiving placebo. A mean decrease in heart rate of 5 to 10 beats per minute was observed in patients receiving this drug, while a mean decrease of 2 to 5 beats per minute was observed in placebo patients. Blood pressure increases of 2 to 3 mmHg were observed in patients receiving 200 mg of this drug compared to a mean increase of up to 1 mmHg in placebo patients. In healthy patients over 65 years, a mean increase of 7 mmHg was observed in patients receiving this drug compared with 4 mmHg in placebo patients. By 2 hours, no difference in blood pressure compared to placebo were found. This drug has not been well studied in patients with ischemic heart disease.

Respiratory

• Frequency not reported: Dyspnea

Dyspnea was reported in less than 2% of patients receiving this drug, but more frequently than those receiving placebo.

Ocular

• Frequency not reported: Visual impairment

Visual impairment was reported in less than 2% of patients receiving this drug, but more frequently than those receiving placebo.

Other

• Common (1% to 10%): Fatigue (includes asthenia and malaise)

Gastrointestinal

• Common (1% to 10%): Nausea and/or vomiting

Musculoskeletal

• Common (1% to 10%): Muscle weakness
• Frequency not reported: Muscle spasm, limb discomfort

Muscle spasm and limb discomfort were reported in less than 2% of patients receiving this drug, but more frequently than those receiving placebo.

Psychiatric

• Frequency not reported: Feeling abnormal, anxiety, tremor, restlessness, sleep abnormalities including sleep disturbance and abnormal dreams, confusion, euphoric mood, hallucinations

Feeling abnormal, anxiety, tremor, restlessness, sleep abnormalities including sleep disturbance and abnormal dreams, confusion, euphoric mood, and hallucinations were reported in less than 2% of patients receiving this drug, but more frequently than those receiving placebo.

See also:

Frequently asked questions

• What are the new drugs for the treatment of migraine?
• Is Reyvow a controlled substance?
• What is Reyvow used for and how does it work?

Further information

Reyvow side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer